Drug Profile
Fluticasone furoate/umeclidinium/vilanterol - GSK/Innoviva/Theravance Biopharma
Alternative Names: BREO ELLIPTA/RELVAR; Elebrato Ellipta; FF/UMEC/VI; fluticasone furoate+ vilanterol + umeclidinium bromide; Fluticasone Furoate/Umeclidinium/Vilanterol Trifenatate; Fluticasone furoate/vilanterol/umeclidinium; GSK 2834425; GW 685698/GSK 573719/GW 642444; GW685698 + GW642444 + GSK573719; ICS/LABA/LAMA - GSK; ICS/LAMA/LABA - GSK; RELVAR/BREO ELLIPTA; TRELEGY ELLIPTA; Trelegy Ellipta; UMEC/VI/FF; Umeclidinium/fluticasone furoate/vilanterol; Umeclidinium/vilanterol/fluticasone furoate; Vilanterol/fluticasone furoate/umeclidinium; Vilanterol/umeclidinium/fluticasone furoateLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Theravance
- Developer GSK; Innoviva; Theravance Biopharma
- Class Androstadienes; Anti-inflammatories; Antiasthmatics; Benzhydryl compounds; Bronchodilators; Chlorobenzenes; Ethers; Glucocorticoids; Phenols; Quinuclidines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 29 Jul 2021 Phase-III clinical trials in Asthma (Treatment-experienced) in China (Inhalation) (NCT04937387)
- 24 Jun 2021 GlaxoSmithKline plans a phase III trial for Asthma in China (Inhalation) in July 2021 (NCT04937387)
- 14 May 2021 Interim efficacy data from the phase III IMPACT trial in Chronic obstructive pulmonary disease presented at the 117th International Conference of the American Thoracic Society (ATS-2021)